With an estimated 8000 rare diseases, there is a need to increase the volume of rare disease research, improve coordination to maximise research investments and ultimately speed up the translation of research into clinical phases and beyond
The International Rare Disease Research Consortium (IRDiRC) is coordinating and fostering international collaborative research on rare diseases in order to overcome the challenges of orphan drug development in particular conducting clinical trials with scarce and widely distributed patients, experts and budgets.
As well as engaging with the leaders of the IRDiRC, by attending the World Orphan Drug Congress 2011 on the 29th November – 1st December, you will be able to contribute to the future of global rare disease research and interact with leading patient groups:
· Hear from John Crowley, CEO, Amicus Therapeutics, on his patient focused approach to clinical trial design as a father, patient advocate and entrepreneur.
· Discover how Genethon are undertaking rare disease research as a non-profit pharma company, and how to solve funding issues from Director General & CEO, Frédéric Revah.
· Learn about the new global registry of patient registries and how you can be part of a developing online rare disease community.
Don’t miss out on the leading orphan drug event and registhttps://secure.terrapinn.com/V5/rCalc.aspx?E=4157 er now to save a staggering €660